TPD Disease Landscape Webinar
Targeted Protein Degradation continues to progress as a therapeutic area with huge potential, and 2023 is shaping up to be a landmark year for the degradation community. As we advance highly valuable degrader compounds closer to the clinic, we were thrilled to present to the community at the recent 3rd Targeted Protein Degradation Summit.
Offering the opportunity to explore the data delivered, this session provided a deep dive into the pipeline, including:
An overview of the current TPD landscape
A deep-dive into the oncology scope exploring preclinical and clinical indications
Insights into the emerging non-oncology indications for novel degrader and stabilizer technologies
The immune tolerance landscape is nothing but dynamic; in our recent webinar, our expert panel discussed the obstacles in treating autoimmune diseases with T Cell therapy approaches and the strategies the developers are utilizing to overcome these obstacles. Key aspects explored included:
- A comprehensive overview of the competitive T Cell therapy within the immune-mediated disease space
- Insights into the emerging trends of Treg therapies
- A picture of what we can likely expect ahead based on recent approvals and late-stage activity
Our Experts
Rachel East
House Speaker
Lead Research Analyst
Beacon
Frank Plowden
Moderator
Account Manager
Beacon
You May Also Be Interested In…
Learn More About TPD
- The Most Comprehensive Way to Search the TPD Drug Development Landscape: Unique search ontologies based on TPD drug and trial characteristics
- Market Leading Approach to TPD Preclinical & Clinical Data Curation: Manual curation of key TPD research and development data points by TPD research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search TPD company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
